MoMa Signature During Granulomatosis

Tuberculosis Clinical Trial

— MOSAR  

Official title:

Role of Monocytes (Mo) and Macrophages (Ma) in Sarcoidosis and in Tuberculosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05916638
• Other study ID #: APHP230273
• Secondary ID: 2022-A02637-36
• Status: Recruiting
• Start date: January 15, 2024
• Est. completion date: October 2025

Study information

• Verified date: March 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Karim Sacre, MD-PhD, PU-PH
• Phone: 0140256019
• Email: karim.sacre[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.

Description:

"Sarcoidosis is an inflammatory disease characterized by the presence of coalescing, tightly clustered, non-necrotizing granulomas. The diagnosis is based on three major criteria: a compatible clinical presentation, the presence of non-necrotizing granulomatous inflammation, and the exclusion of alternative granulomatous diseases. A wide range of clinical phenotypes are observed depending on the location of the granulomatous lesions which can affect any organ, with the lungs being the most affected site. Sarcoidosis shares many similarities with tuberculosis, in which granuloma formation is triggered by Mycobacterium tuberculosis (M. tb). These phenotypic similarities between the two diseases present many challenges for diagnosis, clinical management and therapy.

Our understanding of the factors that contribute to sarcoidosis development, granuloma formation and maintenance remains limited. Part of this challenge is that granuloma development may involve both environmental and genetic factors, which contribute to the recruitment of immune cells to form the granuloma. Immune cells involved in the granuloma include (1) CD4 Th1 and Th17 T cells and their associated cytokines (e.g, IFNγ, TNFα, IL-17, IL-2); and (2) monocytes (Mo) and macrophages (Ma) including proinflammatory M1 and pro-fibrosis M2 types. However, the specific factors that contribute to granuloma maintenance and evolution remain to be identified. Among them, we can hypothesized that trained immunity, persistence of the antigen, or the microenvironment are involved in this chronic dysregulated immune response. Such an improved understanding of the pathophysiology of the disease may allow development of new treatments, as currently corticosteroids remain the mainstay of therapy.

Our main hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT&Tag. The MoMa systemic signature will be defined ex vivo at different time points (M0, M6 and M12) during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory."

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Male and female > 18 years old

2. Diagnosis of sarcoidosis and of tuberculosis

3. Affiliated to medical insurance

Exclusion criteria:

1. HIV infection

2. pregnant or breastfeeding woman

3. Patient under legal protection, guardianship or curators

4. Absence of signed consent"

Related Conditions & MeSH terms

• Sarcoidosis
• Tuberculosis

Intervention

Other:
• blood sample
blood sample collection

Locations

Country	Name	City	State
France	Hôpital Bichat	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	macrophage activation in sarcoidosis measured by epigenomic	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	monocyte activation in sarcoidosis measured by epigenomic	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	macrophage activation in sarcoidosis measured by flow cytometry	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	monocyte activation in sarcoidosis measured by flow cytometry	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	monocyte activation in sarcoidosis measured by transcriptomic	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	macrophage activation in sarcoidosis measured by transcriptomic	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	macrophage activation in sarcoidosis measured by cytokine measurement	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Primary	monocyte activation in sarcoidosis measured by cytokine measurement	performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood	up to 12 months of follow-up.
Secondary	monocyte activation in tuberculosis measured by epigenomic		up to 12 months of follow-up.
Secondary	Identification of a pathogen that triggers sarcoidosis development by metagenomic study		Samples collected before treatment/at diagnosis
Secondary	identification of epigenetic modifications of monocytes by CUT&Tag method	CUT&Tag-sequencing, also known as cleavage under targets and tagmentation, is a method used to analyze protein interactions with DNA	12 months of follow-up.
Secondary	Identification of a diagnostic test to discriminate sarcoidosis and tuberculosis	measurement of IFN? secretion by whole blood in response to stimulation by tuberculosis antigen	Samples collected before treatment/at diagnosis